Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 12/20 | 0.64 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 4/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21736618 | 1.00 | KLKB1 (0.64) | KLKB1RBP4KDM4EPDE5ACFD | |
| SCHEMBL31741508 | 1.00 | KLKB1 (0.64) | KLKB1RBP4KDM4EPDE5ACFD | |
| SCHEMBL31741488 | 0.90 | KLKB1 (0.65) | KLKB1RBP4CFD | |
| SCHEMBL21736641 | 0.90 | KLKB1 (0.65) | KLKB1RBP4CFD | |
| SCHEMBL26310264 | 0.90 | KLKB1 (0.65) | KLKB1RBP4CFD | |
| SCHEMBL21736634 | 0.89 | KLKB1 (0.65) | KLKB1KDM4ECFD | |
| SCHEMBL21736858 | 0.88 | KLKB1 (0.64) | KLKB1 | |
| SCHEMBL31741485 | 0.88 | KLKB1 (0.64) | KLKB1 | |
| SCHEMBL24918401 | 0.87 | KLKB1 (0.52) | KLKB1OPRK1 | |
| SCHEMBL21713084 | 0.81 | KLKB1 (0.43) | KLKB1KDM4ECFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885RBP4 3590/4885KDM4E 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.